Zobrazeno 1 - 10
of 123
pro vyhledávání: '"zhonghua Tao"'
Autor:
Mengdi Yang, Jianing Cao, Tiantian Liu, Bin Li, Jinyan Wang, Shuangyue Pan, Duancheng Guo, Zhonghua Tao, Xichun Hu
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 11, Pp n/a-n/a (2024)
Abstract Background Triple‐negative breast cancer (TNBC) is distinguished by a significant likelihood of distant recurrence and an unfavourable prognosis. However, the underlying molecules and mechanisms have not been fully elucidated. Methods We i
Externí odkaz:
https://doaj.org/article/9e2acecfa8964c78b3be8b52b30d265d
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Breast cancer (BC) is the most common malignant tumor worldwide. Despite enormous progress made in the past decades, the underlying mechanisms of BC remain further illustrated. Recently, TRIM family proteins proved to be engaged in BC progre
Externí odkaz:
https://doaj.org/article/f219fbd496eb46a4b2df42427eec6c00
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15881-15892 (2023)
Abstract Background Bilateral primary breast cancer (BPBC) is a rare type of breast cancer. Studies on the clinicopathologic and molecular characteristics of BPBC in a metastatic context are very limited. Methods A total of 574 unselected metastatic
Externí odkaz:
https://doaj.org/article/25fe8b5d63824ac09ce5247361d74aa5
Autor:
Juan Jin, Bin Li, Jianing Cao, Ting Li, Jian Zhang, Jun Cao, Mingchuan Zhao, Leiping Wang, Biyun Wang, Zhonghua Tao, Xichun Hu
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background Novel human epidermal growth factor receptor 2 (HER2)-directed antibody–drug conjugates prompt the identification of the HER2-low subtype. However, the biological significance of HER2-low expression in breast cancer is unclear.
Externí odkaz:
https://doaj.org/article/feeb8b6d8ae14d6982b8b819747c5496
Autor:
Jinyan Wang, Zhonghua Tao, Biyun Wang, Yizhao Xie, Ye Wang, Bin Li, Jianing Cao, Xiaosu Qiao, Dongmei Qin, Shanliang Zhong, Xichun Hu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionCuproptosis is a novel copper-dependent regulatory cell death (RCD), which is closely related to the occurrence and development of multiple cancers. However, the potential role of cuproptosis-related genes (CRGs) in the tumor microenviron
Externí odkaz:
https://doaj.org/article/2f2048a5fb744a92a075b6d11cc138f4
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on breast cancer ferroptosis remains t
Externí odkaz:
https://doaj.org/article/0d39dc085ee04ecfbb3306d0f32b1da5
Autor:
Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Visceral metastases account for 48–67% of metastatic breast cancer (MBC) patients and presage a worse overall survival. Previous study suggested potential effect of nab-paclitaxel on patients with visceral metastases subgroups.
Externí odkaz:
https://doaj.org/article/8b66bb85b7d0499482ca3c9ffebd7fdc
Autor:
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 13 (2022)
Purpose: Weekly gemcitabine + paclitaxel (wGT) administration is widely applied in real-world clinical practice. The 28-day and 21-day regimens of wGT are the most widely accepted regimens. We evaluated the efficacy and safety of wGT administration i
Externí odkaz:
https://doaj.org/article/9d8349ec24df4118a29d8a50147b661e
Autor:
Jinyan Wang, Dongmei Qin, Zhonghua Tao, Biyun Wang, Yizhao Xie, Ye Wang, Bin Li, Jianing Cao, Xiaosu Qiao, Shanliang Zhong, Xichun Hu
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
IntroductionCuproptosis is a novel identified regulated cell death (RCD), which is correlated with the development, treatment response and prognosis of cancer. However, the potential role of cuproptosis-related genes (CRGs) in the tumor microenvironm
Externí odkaz:
https://doaj.org/article/6c9417c0b97a4c35abdfab5a18b1183a
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundPucotenlimab, also called HX008, is a humanized anti-PD-1 antagonist IgG4 mAb. It blocks programmed cell death protein 1 (PD-1), programmed-death ligand 1 (PD-L1), and programmed death ligand-2 (PD-L2). In the CBCSG 006 trial, gemcitabine p
Externí odkaz:
https://doaj.org/article/4e1206e1919b4ed2be705a990d790246